Long-term treatment outcomes of pediatric low-grade gliomas treated at a university-based hospital

doi:10.21203/rs.3.rs-1876646/v1

Purpose

A multimodality approach is generally considered for pediatric low-grade gliomas (LGG); however, the optimal management remains uncertain. The objective of the study was to evaluate treatment outcomes of pediatric LGG, focusing on long-term survival and factors related to outcomes.

Methods

A retrospective review of 77 pediatric LGG cases treated at Ramathibodi Hospital, Thailand between 2000 and 2018 was performed. The inclusion criteria were all pediatric LGG cases aged ≤ 15 years. Diffuse intrinsic pontine gliomas and spinal cord tumors were excluded.

Results

The median follow-up time was 8.2 years (range, 0.6–19.7). The median age at diagnosis was 6.2 years (interquartile range, 3.6–11.4). Treatments included surgery (71%), chemotherapy (40%), and radiation therapy (14%). The 10-year overall survival (OS) and 10-year progression-free survival were 94% and 59%, respectively, for the entire cohort. The 10-year OS was 100% in three subgroups of patients: pilocytic subtype, WHO grade 1 tumors, and receipt of gross total resection. After multivariable analysis, older age and no surgery had a significant negative impact on OS.

Conclusions

Excellent outcomes can be achieved in pediatric LGG patients using a multidisciplinary approach. Gross total resection is the standard primary treatment. Chemotherapy is the alternative standard treatment in incomplete resection cases, unresectable patients, or patients with progressive disease. Radiation therapy should be reserved as a salvage treatment option because of late complications that usually affect patients’ quality of life.

Pediatric low-grade glioma

PLGG

intracranial

survival

Pediatric low-grade gliomas (LGG) are defined as World Health Organization (WHO) criteria grade 1 and 2 tumors with at least some glial cell lineage components, and they are the most frequent primary childhood central nervous system tumors [1–4]. The prognosis is excellent when complete tumor resection is achieved. However, complete resection is not feasible in all LGG patients, mainly because of tumor location. Chemotherapy and radiation therapy (RT) are used as adjuvant treatment after partial resection (PR) or primary treatment for unresectable tumors. Nevertheless, there is no standard guideline for the management of post-surgical residual or unresectable cases, which is generally based on individual institute experience. Currently, chemotherapy is commonly offered, whereas RT is only administered occasionally because of the concerning long-term complications, especially in younger patients [2, 5]. The literature regarding long-term outcomes in pediatric LGG patients treated with a multimodality approach remains limited. This study aimed to evaluate the long-term treatment outcomes in pediatric LGG, focusing on long-term survival and factors related to outcomes at a university-based institute.

Patient population

Data on pediatric LGG patients treated at Ramathibodi Hospital, Bangkok, Thailand between January 2000 and January 2018 were retrospectively reviewed and analyzed. The inclusion criteria were a diagnosis of pediatric LGG and patient age of 15 years or younger at the time of diagnosis. All patients were diagnosed by histological confirmation of WHO grade 1 or 2 glial cell tumors, except for patients with unresectable tumors, who were diagnosed by magnetic resonance imaging (MRI). Patients diagnosed with diffuse intrinsic pontine gliomas and spinal cord tumors were excluded from the study. The study was approved by the Ethical Committee of the Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Clinical characteristics

Demographic data included age at diagnosis, sex, histology subtype, tumor location, and tumor size. Tumor grade was defined following the WHO grade classification. Details on surgical resection, chemotherapy, and RT as the first course of treatment were identified. The extent of resection was categorized into four groups based on the surgeon’s operative report and postoperative MRI: gross total resection (GTR), subtotal resection (STR), PR, and biopsy/no surgery [6].

Overall management policy

In each pediatric LGG case treated in our institute, maximal safe resection with complete tumor removal was performed when feasible. In general, patients who underwent complete resection did not receive any adjuvant treatment. For patients who received incomplete resection, whether to proceed with adjuvant treatment was discussed in a pediatric tumor board meeting. Although there are no standard guidelines for adjuvant treatment in post-surgical residual or unresectable cases, we created a multidisciplinary team and developed national protocols for treatment. On the basis of our protocol, upfront chemotherapy is the standard regimen for high-risk recurrence and pediatric LGG recurrence. RT is usually offered as salvage treatment after unsuccessful redo surgery or multicourse chemotherapy.

Chemotherapy protocol

The chemotherapy regimens were 1) vinblastine 6 mg/m² per week and 2) carboplatin 560 mg/m² every 3–4 weeks combined with vincristine 1.5 mg/m² per week.

RT

The RT technique, treatment volume, and radiation dose were mainly based on physician preference, and the era in which the patient was treated. In the earlier period of the study, patients were treated via a 2-dimensional RT technique using a cobalt-60 machine (Theratron Elite 80; MDS Canada Inc., Kanata, Canada). Since 2007, we have used a 2100C linear accelerator (Varian Medical Systems, Palo Alto, CA, USA), which was later replaced with a Clinic IX machine (Varian Medical Systems) and the Edge Radiosurgery system (Varian Medical Systems). More advanced RT techniques such as three-dimensional conformal RT, intensity-modulated RT, and volume metric arc therapy were used for most patients. Local-field radiation with a total dose of 45–54 Gy and daily doses of 1.8–2 Gy/fraction was commonly used in the study.

Assessment of outcomes and complications

Clinical assessment combined with neurological examination and MRI was regularly performed to assess outcomes. Follow-up examinations were conducted every 3 months for the first 2 years, followed by every 6 months for 5 years and then annually. The information regarding long-term treatment-related outcomes, neurological status, endocrine function, hearing status, visual acuity, cerebral vasculopathy, and secondary tumors was identified. Imaging follow-up was performed every 3–6 months for the first 2 years and then annually. Radiologic response was reported according to the Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria [7].

Statistical analysis

Categorical data were presented as frequencies and percentages, and continuous data were shown as the median and interquartile range (IQR) or range. Overall survival (OS) was calculated as the time from the date of diagnosis to the date of death or the last follow-up. Progression-free survival (PFS) was defined as the time from the date of first treatment to the date of the first documented intracranial progression/recurrence by RAPNO criteria, all-cause death, or last follow-up. Survival was calculated using the Kaplan–Meier method. The log-rank test was used to compare differences in survival curves in univariate analysis. Variables with p<0.05 were considered statistically significant and further analyzed in the multivariate Cox proportional hazard model. Statistical analyses were performed using STATA software (17.0, StataCorp, College Station, TX, USA)

Patient characteristics

From January 2000 to January 2018, 94 patients were assessed for eligibility. Seventeen patients were excluded from the analysis because of exclusion criteria (n = 11) and insufficient information (n = 6). Thus, 77 patients were included in the analysis. There were 46 (60%) boys and 31 (40%) girls with a median age at diagnosis of 6.2 years (IQR, 3.6–11.4 years). The main tumor subtypes were pilocytic astrocytoma (51%) and diffuse astrocytoma (31%). Diagnosis based on imaging only was reported in 8% of patients. Forty patients (57%) had WHO grade 1 tumors, while 30 patients (43%) had WHO grade 2 tumors. Four patients (5%) were diagnosed with neurofibromatosis type 1. The median tumor size was 3.7 cm (IQR, 2.6–4.6 cm). The tumor location was the infratentorial region in 27 cases (35%), supratentorial region in 23 cases (30%), optic pathway in 16 cases (21%), and midline region in 11 cases (14%). The baseline patient and tumor characteristics were summarized in Table 1.

Table 1

Characteristics of pediatric LGGs for the entire cohort at first diagnosis
	Total (n = 77)	Chemotherapy (n = 28)	RT (n = 5)
Sex Male Female	46 (60%) 31 (40%)	14 (50%) 14 (50%)	3 (60%) 2 (40%)
Median age at diagnosis (years, range)	6.2 (3.6–11.3)	3.3 (1.3–8.8)	10 (3–13)
Neurofibromatosis 1	4 (5%)	2 (7%)	0
Location Supratentorial Infratentorial Optic pathway Midline	23 (30%) 27 (35%) 16 (21%) 11 (14%)	12 (43%) - 12 (43%) 4 (14%)	1 (20%) 1 (20%) 1 (20%) 2 (40%)
Median tumor size (cm, range)	3.7 (2.6–4.6)	6 (0.3–14.7)	4 (2.3–6.9)
Histology Pilocytic astrocytoma Diffuse astrocytoma, grade 2 Low-grade glioma NOS No histologic diagnosis	39 (51%) 24 (31%) 8 (10%) 6 (8%)	10 (35%) 12 (43%) 3 (10%) 3 (10%)	0 4 (80%) 1 (20%) 0
WHO grade Grade 1 Grade 2	40 (57%) 30 (43%)	10 (36%) 15 (50%)	0 5 (100%)
Extent of resection Gross total resection Subtotal resection Partial resection Biopsy No resection	33 (43%) 5 (6%) 17 (22%) 17 (22%) 5 (7%)	2 (7%) 1 (4%) 11 (39%) 11 (39%) 3 (10%)	1 (20%) 0 2 (40%) 2 (40%) 0

Treatment modalities at the first diagnosis

Among 77 patients, surgical resection was performed in 55 patients (71%). The extent of resection was GTR in 33 patients (43%), STR in 5 patients (6%), and PR in 17 patients (22%). Twenty-two patients (29%) received only biopsy or no surgical resection because of extensive diffuse intracranial tumors or optic pathway locations. No severe complications or deaths occurred during the perioperative period. No patients who received GTR underwent any adjuvant treatment, except for two patients in the GTR group who received adjuvant chemotherapy and RT because of a concern for microscopic residual disease because the lesion was located in the optic pathway and midline region.

Forty-four patients who received surgery less than GTR were administered further treatment modalities, including chemotherapy in 28 patients (59%) and RT in five patients (13%). The remaining 11 patients (27%) underwent observation even though they had a residual tumor. The reasons for observation included young age, WHO grade 1 and family preference.

Among 28 patients who received chemotherapy, 14 patients received treatment in an adjuvant setting, while 14 patients received treatment as definitive therapy. Chemotherapy consisted of vinblastine (71%), carboplatin/vincristine (16%), and miscellaneous regimens (13%). The median duration of chemotherapy was 0.68 years (IQR, 0.33–2.00 years).

Among five patients who received RT, two received RT as part of adjuvant treatment after PR, and three received RT as definitive treatment. All patients were treated locally with a median total radiation dose of 54 Gy (range, 39.6–54 Gy) via conventional fractionation. The radiation technique also varied over time and included 2-dimensional RT (36%), 3-dimensional conformal RT (45%), and intensity-modulated RT (18%). The baseline and treatment characteristics of 77 patients were summarized in Table 1.

Disease course after initial management

The median follow-up time was 8.2 years (range, 0.6–19.7 years). At the last follow-up, 71/77 patients were alive, including 36 patients with stable disease, 33 with complete responses, and two patients with recent disease progression who were still receiving chemotherapy.

Overall, 29/77 patients (38%) developed tumor progression once (n = 9) or up to four times (n = 20) following GTR (n = 5), PR (n = 5), chemotherapy alone (n = 8), adjuvant postoperative chemotherapy (n = 8), adjuvant RT (n = 1), and adjuvant chemoradiotherapy (n = 2). The median time to first progression was 1.2 years (range, 0.1–6.9 years). Most cases of tumor progression were localized disease (96%), while only one patient (4%) who had intraventricular grade 2 glioma developed local recurrence with leptomeningeal spreading. Radiation-induced secondary tumors occurred in two patients. The first patient initially had grade 2 astrocytoma in the cerebellum that was previously treated with adjuvant chemoradiotherapy. Three years later, the primary tumor was enlarged, and tumor removal was performed. The pathological report indicated glioblastoma multiforme. Another patient developed intracranial meningioma 15 years after being diagnosed with diffuse thalamic astrocytoma and treated with definitive RT. The meningioma was successfully removed, and he is still alive without disease.

Six patients died. Five deaths were related to tumor progression, including one after malignant transformation, and one patient with local tumor control died from an unrelated severe pneumonia infection.

Survival analysis

For the entire cohort, the 10-year OS and PFS were 94% (95% confidence interval [CI] 83–98) and 59% (95% CI, 49–71%), respectively (Figs. 1). Patients with the pilocytic subtype, those with WHO grade 1 tumors, and those who underwent GTR had a 10-year OS of 100% (Fig. 2). Univariate analysis showed that older age at diagnosis, no surgery, and RT were significantly associated with worse OS. However, after multivariate testing, the factors that remained significantly associated with worse OS were older age at diagnosis (hazard ratio [HR] = 1.38, p = 0.025) and no surgery (HR = 11.11, p = 0.027) (Table 2). WHO grade 2 tumor was an independent prognostic factor for inferior PFS in both univariate and multivariate analysis (HR = 8.07, p = 0.007).

Table 2

Univariate and multivariate analyses for factors predicting OS
Factors	Univariate analysis HR (95% CI)	p-value	Multivariate analysis HR (95% CI)	p-value
Sex (male vs. female)	0.74 (0.13–410)	0.73
Age at diagnosis	1.35 (1.04–1.75)	0.024*	1.38 (1.04–1.84)	0.025*
Pilocytic astrocytoma (yes vs. no)	No event	1.00
WHO group (2 vs. 1)	No event	1.00
Tumor size (cm)	1.11 (0.70–1.74)	0.66
Tumor location (cerebellum vs. other)	0.35 (0.04–3.04)	0.34
GTR (yes vs. no)	No event	1.00
Surgical treatment (no or yes)	12.5 (1.37–104.07)	0.025*	11.11 (1.32–100.07)	0.027*
RT used (yes vs. no)	17.23 (1.95–151.95)	0.010
CMT used (yes vs. no)	4.38 (0.79–24.37)	0.23
CMT or RT used (yes vs. no)	5.49 (0.63–47.73)	0.12

Management after tumor progression

Tumor progression developed in 29 patients with a median time of 1.2 years (range, 0.1–6.9) after the first management. Additional surgery for tumor progression was performed in 13 patients (13/29; 45%). Nine patients received GTR, whereas four patients had a residual tumor after re-operation that was further treated with adjuvant chemotherapy in three patients and chemoradiation in one patient. Sixteen patients (16/29; 55%) did not receive re-operation because of a diffuse pattern, tumor adhesion to critical structures, clinical progression only, multiple metastases in the brain and spine, or family preference. Among these 16 patients, 12 received repeated courses of chemotherapy, three patients received chemoradiation, and only one patient received RT alone. The chemotherapy regimen for salvage treatment was vinblastine (43%) and various combinations of carboplatin, vincristine, irinotecan, or temozolomide. All patients received local RT as salvage treatment, except one patient with multiple recurrences in the brain and spine who received craniospinal irradiation. No patient received re-irradiation in this study.

In total, 13 of 29 patients required multiple courses of chemotherapy and multimodality treatment because of repeated tumor progression. Following multiple treatments, seven patients were alive with a stable primary tumor, one patient with primary progression and leptomeningeal spreading showed stable disease after craniospinal irradiation and repeated courses of chemotherapy, and five patients died as a result of an uncontrolled tumor.

Treatment-related complications

No deaths or permanent focal neurologic deficits were caused by tumor resection. The acute toxicities of chemotherapy differed depending on the type of chemotherapy. Grade 3–4 febrile neutropenia occurred more often with carboplatin-based regimens than with the vinblastine regimen, which frequently caused mild side effects. The acute chemotherapy side effects included grade 3–4 febrile neutropenia in nine patients, grade 2 transaminitis in two patients, and grade 4 allergic reaction in one patient. Late sequelae presumably related to RT included endocrine dysfunction (n = 2), morbid obesity (n = 2), azoospermia (n = 1), malignant transformation (n = 1), and secondary meningioma (n = 1).

Developments in the advanced management of pediatric LGG, including surgery, RT, and systemic treatment, have led to improved outcomes. Excellent long-term survival after GTR has been reported in several studies. The risk for tumor recurrence in patients who undergo complete tumor resection is extremely low [8–10]. For patients with incomplete tumor resection or unresectable tumors, appropriate non-surgical management can include observation, traditional chemotherapy, and RT. Information regarding the extent and type of initial surgical interventions and clinical symptoms of the patient is essential to decide the type of further adjuvant treatment. Tumor progression after incomplete resection occurs independent of tumor location, and observation is justified in patients without tumor-related symptoms and those with small residual tumors [2, 8, 10, 11]. Delaying the start of non-surgical treatment, including chemotherapy or RT, may increase the risk of irreversible neurologic impairment and may be associated with a potentially lower probability of tumor control. Nevertheless, there are no apparent differences in long-term OS following immediate versus delayed RT or chemotherapy [12–15]. Generally, immediate non-surgical management is considered in patients with significant neurologic or visual symptoms at diagnosis or in all infants < 1 year of age with chiasmatic/hypothalamic glioma with a residual tumor independent of neurologic and/or visual symptoms [2].

The value of RT in improving PFS is well documented [16]. However, RT is associated with numerous long-term complications, such as neurocognitive impairment, endocrinopathy, vasculopathy, and secondary tumors, especially in children under 5 years of age [17–19]. Therefore, chemotherapy is accepted as the primary non-surgical treatment for pediatric LGG patients regardless of age, histology, and site to improve PFS and delay the use of RT [20]. The use of upfront chemotherapy in residual or unresectable pediatric LGGs as a strategy to delay or avoid the neurotoxic effects of RT has been used in our institute for many years. Thus, the main objective of this study was to report the long-term outcomes of a relatively large number of pediatric LGG patients treated with a comprehensive strategy following the university-based institute protocol.

In the current study, the excellent OS rate of 94% at 10 years was comparable to the range in several previous studies that reported 5- to 10-year OS rates between 80% and 90% [21, 22]. However, the PFS rates of 23–50% were lower than the OS rates [8, 9, 20, 23–25]. These findings suggested the importance of regular long-term follow-up, early detection of disease progression, and comprehensive salvage treatment. In our study, among 12 patients who underwent partial tumor resection without non-surgical adjuvant treatment, nearly half (42%) developed tumor progression. However, successful salvage tumor resection was performed. This reflected the fact that in pediatric LGG tumor recurrence cases, the tumor remained well localized to the initial site without increased invasiveness. This pattern of progression made the lesion responsive to repeat resection followed by adjuvant treatment if indicated. Careful neurosurgical follow-up is necessary for successful salvage surgery.

Prognostic factors affecting survival varied between previous studies; however, widely accepted important factors included the extent of surgical resection, pilocytic subtype, WHO grade, and patient age [8, 9, 12, 21, 23]. Consistent with previous studies, the current study confirmed the excellent OS of 100% in three patient subgroups: pilocytic astrocytoma, WHO grade 1 tumor, and receipt of GTR.

Pilocytic astrocytomas have a better prognosis than most other non-pilocytic subtypes. After GTR, the OS and PFS rates reported in several studies were 75–100% [9, 12, 26]. In cases of PR without any adjuvant treatment, the 5-year PFS rate was 50–60% [10, 27]. It is unclear whether this is because pilocytic tumors are usually well circumscribed and more responsive to GTR than non-pilocytic gliomas or whether they represent a more biologically favorable tumor [10].

Numerous previous studies [9, 10] reported that a greater extent of resection was correlated with better OS and PFS; however, the extent of resection was not associated with a statistically significant improvement in OS in our study. Nevertheless, patients who received any surgery showed better OS, with a 10-year OS of 98%, compared with 85% for patients who underwent biopsy and no surgery (HR = 11.1, p = 0.027). Surgical resection not only achieved an excellent OS rate but also prolonged PFS following one or repeated tumor resections without requiring adjuvant treatment in 58% of patients in the present cohort. This finding highlights the importance of surgery independent of the extent of resection.

Patient age was previously reported to be associated with survival in various studies of pediatric LGGs in all locations; however, the prognostic impact of older or younger age in pediatric LGG remains inconclusive. Age younger than 1–2 years at diagnosis was reported as an unfavorable prognostic factor by some studies [8, 9, 20, 21, 23, 24, 28]. Moreover, age older than 8–12 years has been shown to be associated with better or impaired prognosis, depending on an unfavorable histology [23] or tumor site [20]. In our study, older age was shown to be associated with worse OS. The inconsistent results might be due to the retrospective nature of studies or differences in baseline characteristics and treatment modalities, especially the use of adjuvant chemotherapy and RT, which usually depends on the experience at each institution.

Chemotherapy is accepted as the first-line non-surgical treatment in incomplete resection or unresectable pediatric LGG cases. Two randomized control trials [20, 23] and many small studies [8, 9, 20, 23–25] reported similar results for all single drugs and combinations with a high primary tumor control rate of 70–95%; however, none achieved sustainable long-term tumor control with a decline in PFS to below 50% at 5 years. The commonly used chemotherapy regimens in our center include vinblastine- and carboplatin-based regimens based on a previous study [23].

RT is typically applied as conventional fractionated external beam radiation with a total dose of 45–54 Gy. Various RT techniques have achieved high PFS rates of 65–80% and OS rates of 93–98% after 5–10 years [29–33]. The use of postoperative RT showed a PFS benefit in some studies; however, adjuvant RT did not translate to an OS benefit [27, 33]. In addition, RT was associated with malignant transformation and late cognitive and endocrine dysfunction in irradiated patients [27, 32, 34]. Although the present study showed acceptable PFS rates with chemotherapy for residual LGG cases and reported late RT complications, including endocrinopathy and RT-induced secondary tumors, RT should be avoided and chemotherapy administered as upfront therapy for all patients. In some cases that might need RT, a multidisciplinary team approach with modern RT techniques is recommended.

Pediatric LGGs experienced excellent OS with a multimodality approach. Maximal safe resection with complete tumor removal should be performed whenever feasible. Chemotherapy may be the best option for first-line adjuvant treatment, especially in patients with extended tumors and young children. RT should be preserved as salvage treatment after maximum resection and multicourse chemotherapy. Patient-specific decision making is required and should be discussed in a multidisciplinary setting.

Collins KL, Pollack IF (2020) Pediatric low-grade gliomas. Cancers (Basel) 12:x
Gnekow AK, Kandels D, Tilburg CV et al (2019) SIOP-E-BTG and GPOH guidelines for diagnosis and treatment of children and adolescents with low grade glioma. Klin Padiatr 231:107–135
Gilbert M, Lang F (2007) Management of patients with low-grade gliomas. J Abbr 25:1073–1088
Gajjar A, Sanford RA, Heideman R et al (1997) Low-grade astrocytoma: a decade of experience at St. Jude Children’s Research Hospital. J Clin Oncol 15:2792–2799
Cooney T, Yeo KK, Kline C et al (2020) Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma. Neurooncol Pract 7:4–10
Karschnia P, Vogelbaum MA, van den Bent M et al (2021) Evidence-based recommendations on categories for extent of resection in diffuse glioma. Eur J Cancer 149:23–33
Fangusaro J, Witt O, Hernáiz Driever P et al (2020) Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol 21:e305–e316
Gnekow AK, Falkenstein F, von Hornstein S et al (2012) Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro Oncol 14:1265–1284
Stokland T, Liu JF, Ironside JW et al (2010) A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). Neuro Oncol 12:1257–1268
Wisoff JH, Sanford RA, Heier LA et al (2011) Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children’s Oncology Group. Neurosurgery 68:1548–1554 discussion 54–55
Kaufmann A, Gerber NU, Kandels D et al (2018) Management of primary tectal plate low-grade glioma in pediatric patients: results of the multicenter treatment study SIOP-LGG 2004. Neuropediatrics 49:314–323
Fisher PG, Tihan T, Goldthwaite PT et al (2008) Outcome analysis of childhood low-grade astrocytomas. Pediatr Blood Cancer 51:245–250
Garvey M, Packer RJ (1996) An integrated approach to the treatment of chiasmatic-hypothalamic gliomas. J Neurooncol 28:167–183
Gnekow AK, Kortmann RD, Pietsch T, Emser A (2004) Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy -- report from the multicenter treatment study for children and adolescents with a low grade glioma -- HIT-LGG 1996 -- of the Society of Pediatric Oncology and Hematology (GPOH). Klin Padiatr 216:331–342
Müller K, Gnekow A, Falkenstein F et al (2013) Radiotherapy in pediatric pilocytic astrocytomas. A subgroup analysis within the prospective multicenter study HIT-LGG 1996 by the German Society of Pediatric Oncology and Hematology (GPOH). Strahlenther Onkol 189:647–655
Grabenbauer GG, Roedel CM, Paulus W et al (2000) Supratentorial low-grade glioma: results and prognostic factors following postoperative radiotherapy. Strahlenther Onkol 176:259–264
Chadderton RD, West CG, Schuller S, Quirke DC, Gattamaneni R, Taylor R (1995) Radiotherapy in the treatment of low-grade astrocytomas. II. The physical and cognitive sequelae. Childs Nerv Syst 11:443–448
Kortmann RD, Timmermann B, Taylor RE et al (2003) Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part II: treatment-related late toxicity. Strahlenther Onkol 179:585–597
Merchant TE, Kun LE, Wu S, Xiong X, Sanford RA, Boop FA (2009) Phase II trial of conformal radiation therapy for pediatric low-grade glioma. J Clin Oncol 27:3598–3604
Ater JL, Zhou T, Holmes E et al (2012) Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group. J Clin Oncol 30:2641–2647
Bandopadhayay P, Bergthold G, London WB et al (2014) Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer 61:1173–1179
Rozen WM, Joseph S, Lo PA (2008) Spontaneous regression of low-grade gliomas in pediatric patients without neurofibromatosis. Pediatr Neurosurg 44:324–328
Gnekow AK, Walker DA, Kandels D et al (2017) A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤ 16 years) low grade glioma - A final report. Eur J Cancer 81:206–225
Laithier V, Grill J, Le Deley MC et al (2003) Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy–results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol 21:4572–4578
Opocher E, Kremer LC, Da Dalt L et al (2006) Prognostic factors for progression of childhood optic pathway glioma: a systematic review. Eur J Cancer 42:1807–1816
Fouladi M, Hunt DL, Pollack IF et al (2003) Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Children’s Cancer Group high-grade glioma study CCG-945. Cancer 98:1243–1252
Pollack IF, Claassen D, al-Shboul Q, Janosky JE, Deutsch M (1995) Low-grade gliomas of the cerebral hemispheres in children: an analysis of 71 cases. J Neurosurg 82:536–547
Mirow C, Pietsch T, Berkefeld S et al (2014) Children < 1 year show an inferior outcome when treated according to the traditional LGG treatment strategy: a report from the German multicenter trial HIT-LGG 1996 for children with low grade glioma (LGG). Pediatr Blood Cancer 61:457–463
Marcus KJ, Goumnerova L, Billett AL et al (2005) Stereotactic radiotherapy for localized low-grade gliomas in children: final results of a prospective trial. Int J Radiat Oncol Biol Phys 61:374–379
Merchant TE, Conklin HM, Wu S, Lustig RH, Xiong X (2009) Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits. J Clin Oncol 27:3691–3697
Paulino AC, Mazloom A, Terashima K et al (2013) Intensity-modulated radiotherapy (IMRT) in pediatric low-grade glioma. Cancer 119:2654–2659
Greenberger BA, Pulsifer MB, Ebb DH et al (2014) Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas. Int J Radiat Oncol Biol Phys 89:1060–1068
Youland RS, Khwaja SS, Schomas DA, Keating GF, Wetjen NM, Laack NN (2013) Prognostic factors and survival patterns in pediatric low-grade gliomas over 4 decades. J Pediatr Hematol Oncol 35:197–205
Krishnatry R, Zhukova N, Guerreiro Stucklin AS et al (2016) Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: A population-based study. Cancer 122:1261–1269

No competing interests reported.

Long-term treatment outcomes of pediatric low-grade gliomas treated at a university-based hospital

Archived Versions:

Version 1

Abstract

Purpose

Methods

Results

Conclusions

Figures

Introduction

Materials And Methods

Results

Discussion

Conclusion

References

Additional Declarations

Archived Versions:

Version 1